Advanced search
Publication Cover
Acta Oncologica Volume 50, 2011 - Issue 1
Journal homepage
812
Views
3
CrossRef citations to date
0
Altmetric
Letter

New recommendation of doses in an ongoing phase II study of docetaxel, oxaliplatin and capecitabine as first line therapy in advanced gastro-oesophageal cancer

Katrine R. Schønnemann Department of Oncology, Odense University Hospital, Odense, Denmark; Institute of Clinical Research, University of Southern Denmark, DenmarkCorrespondencek.schø[email protected]
,
Mette Yilmaz Department of Oncology, Aalborg Hospital, Aalborg, Denmark
,
Maria Andersen Department of Oncology, Aalborg Hospital, Aalborg, Denmark
&
Per Pfeiffer Department of Oncology, Odense University Hospital, Odense, Denmark; Institute of Clinical Research, University of Southern Denmark, Denmark
Pages 151-152 | Received 14 Jul 2010, Accepted 15 Jul 2010, Published online: 15 Sep 2010

Citations (3)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Per Pfeiffer, Camilla Qvortrup, Merete Krogh, Katrine Schoennemann, Lene W. Vestermark, Helle A. Jensen & Jon K. Bjerregaard. (2017) S-1 in combination with docetaxel and oxaliplatin in patients with advanced gastro-esophageal adenocarcinoma: two parallel phase 1/2a studies. Acta Oncologica 56:1, pages 46-51.
Read now

Articles from other publishers (2)

Yuan Tian, Qun Zhao, Yong Li, Liqiao Fan, Zhidong Zhang, Xuefeng Zhao, Bibo Tan, Dong Wang & Peigang Yang. (2021) Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma. Gastroenterology Research and Practice 2021, pages 1-7.
Crossref
Maarten J. Deenen, Didier Meulendijks, Henk Boot, Marie-Cecile J. C. Legdeur, Jos H. Beijnen, Jan H. M. Schellens & Annemieke Cats. (2015) Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction. Cancer Chemotherapy and Pharmacology 76:6, pages 1285-1295.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.